Diabetes and Obesity Management - Episode 10

Episode 10 - Additional Sodium Glucose Cotransporter 2 Inhibitors in the Pipeline

Two sodium glucose cotransporter 2 (SGLT-2) inhibitors (canagliflozin and dapagliflozin) have received approval from the FDA. In this segment, Peter Salgo, MD, highlights 2 additional SGLT-2 inhibitors that are currently in the drug pipeline for the treatment of type 2 diabetes mellitus (T2DM).

Jeffrey D. Dunn, PharmD, MBA; Kari Uusinarkaus, MD, FAAFP, FNLA; Dr Salgo; and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss the need for additional SGLT-2 inhibitors and consider how the availability of more treatment options will affect the costs of treating and managing T2DM.

Together, the experts conclude that as new agents continue to emerge, it will be important to assess and compare their effectiveness in specific patient populations.

Dr Handelsman adds that treatment recommendations are expected to be updated as healthcare professionals gain new insight about the use of SGLT-2 inhibitors in clinical practice.

Maria Lopes, MD, MS, hopes that as more experience is gained in matching appropriate patients to appropriate therapies, real-world use will establish the clinical value of SGLT-2 inhibitors.